CD4 and dermatomyositis: To examine the potential for therapeutic intervention for the increased TIGIT+CD226+ CD4 T cell subset in patients with DM, we assessed the functional consequences of CD155, CD112, and anti-CD226 antibody treatments on TIGIT+CD226+ CD4 T cells.